Drug Safety

, Volume 21, Issue 6, pp 489–501 | Cite as

Anticonvulsant Hypersensitivity Syndrome

Incidence, Prevention and Management
  • Sandra R. Knowles
  • Lori E. Shapiro
  • Neil H. Shear
Review Article


Although the anticonvulsant hypersensitivity syndrome was first described in 1950, confusion still abounds regarding the syndrome. The triad of fever, rash and internal organ involvement occurring 1 to 8 weeks after exposure to an anticonvulsant heralds this rare (1 in 1000 to 10 000 exposures) but serious reaction. Aromatic anticonvulsants [phenytoin, phenobarbital (phenobarbitone) and carba-mazepine] are the most frequently involved drugs; however, there have also been several cases of anticonvulsant hypersensitivity syndrome associated with lamotrigine.

Fever, in conjunction with malaise and pharyngitis, is often the first sign. This is followed by a rash which can range from a simple exanthem to toxic epidermal necrolysis. Internal organ involvement usually involves the liver, although other organs such as the kidney, CNS or lungs may be involved. Hypothyroidism may be a complication in these patients approximately 2 months after occurrence of symptoms.

The aromatic anticonvulsants are metabolised to hydroxylated aromatic compounds, such as arene oxides. If detoxification of this toxic metabolite is insufficient, the toxic metabolite may bind to cellular macromolecules causing cell necrosis or a secondary immunological response. Cross-reactivity among the aromatic anticonvulsants may be as high as 75%. In addition, there is a familial tendency to hypersensitivity to anticonvulsants.

Discontinuation of the anticonvulsant is essential in patients who develop symptoms compatible with anticonvulsant hypersensitivity syndrome. A minimum battery of laboratory tests, such as liver transaminases, complete blood count and urinalysis and serum creatinine, should be performed. Corticosteroids are usually administered if symptoms are severe. Patients with anticonvulsant hypersensitivity syndrome should avoid all aromatic anticonvulsants; benzo-diazepines, valproic acid (sodium valproate) or one of the newer anticonvulsants can be used for seizure control. However, valproic acid should be used very cautiously in the presence of hepatitis. There is no evidence that lamotrigine cross-reacts with aromatic anticonvulsants. In addition, family counselling is a vital component of patient management.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Vittorio C, Muglia J. Anticonvulsant hypersensitivity syndrome. Arch Intern Med 1995; 155: 2285–90PubMedCrossRefGoogle Scholar
  2. 2.
    Anonymous. Case records of the Massachusetts General Hospital: weekly clinicopathological exercises. Case 26-1996: a seven-year-old boy with fever, lymphadenopathy, hepatosplenomegaly, and prominent eosinophilia. N Engl J Med 1996; 335: 577-84Google Scholar
  3. 3.
    Konishi G, Naganuma Y, Hongo K, et al. Carbamazepine-induced skin rash in children with epilepsy. Eur J Pediatr 1993; 152: 605–8PubMedCrossRefGoogle Scholar
  4. 4.
    Shear N, Spielberg S. Anticonvulsant hypersensitivity syndrome, in vitro assessment of risk. J Clin Invest 1988; 82: 1826–32PubMedCrossRefGoogle Scholar
  5. 5.
    Haruda F. Phenytoin hypersensitivity: 38 cases. Neurology 1979; 29: 1480–5PubMedCrossRefGoogle Scholar
  6. 6.
    Handfield-Jones S, Jenkins R, Whittaker S, et al. The anticon-vulsant hypersensitivity syndrome. Br JDermatol 1993; 129: 175–7CrossRefGoogle Scholar
  7. 7.
    Tomsick R. The phenytoin syndrome. Cutis 1983; 32: 535–41PubMedGoogle Scholar
  8. 8.
    Prosser T, Lander R. Phenytoin-induced hypersensitivity reactions. Clin Pharm 1987; 6: 728–34PubMedGoogle Scholar
  9. 9.
    Rivey M, Stone J. Carbamazepine hypersensitivity reaction. Brain Inj 1991; 5: 57–62PubMedCrossRefGoogle Scholar
  10. 10.
    Parker W, Shearer C. Phenytoin hepatotoxicity: a case report and review. Neurology 1979; 29: 175–8PubMedCrossRefGoogle Scholar
  11. 11.
    Lane T, Peterson E. Hepatitis as a manifestation of phenobarbital hypersensitivity. South Med J 1984; 77: 94PubMedCrossRefGoogle Scholar
  12. 12.
    Ting S, Dunsky E. Diphenylhydantoin-induced hepatitis. Ann Allergy 1982; 48: 331–2PubMedGoogle Scholar
  13. 13.
    Olsson R, Zettergren L. Anticonvulsant-induced liver damage. Am J Gastroenterol 1988; 83: 576–7PubMedGoogle Scholar
  14. 14.
    Smythe M, Unstead G. Phenytoin hepatotoxicity: a review of the literature. Drug Intell Clin Pharm 1989; 23: 13–8Google Scholar
  15. 15.
    Schlienger R, Shear N. Antiepileptic drug hypersensitivity syndrome. Epilepsia 1998; 39 Suppl.: S3–S7PubMedCrossRefGoogle Scholar
  16. 16.
    Merritt H, Putnam T. Sodium diphenylhydantoinate in treatment of convulsive disorders: toxic symptoms and their prevention. Arch Neurol Psychiatry 1939; 42: 1053–8CrossRefGoogle Scholar
  17. 17.
    Chaiken R, Goldberg B, Segal J. Dilantin sensitivity: report of a case of hepatitis with jaundice, pyrexia and exfoliative dermatitis. N Engl J Med 1950; 242: 897–8PubMedCrossRefGoogle Scholar
  18. 18.
    Tennis P, Stern R. Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: arecord linkage study. Neurology 1997; 49: 542–6PubMedCrossRefGoogle Scholar
  19. 19.
    Schlienger R, Oh P, Knowles S, et al. Quantifying the costs of serious adverse drug reactions to antiepileptic drugs. Epilepsia 1998; 39 Suppl.: S27–S32PubMedCrossRefGoogle Scholar
  20. 20.
    Roujeau JC, Stern R. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272–85PubMedCrossRefGoogle Scholar
  21. 21.
    Spielberg S, Shear N, Hutson N, et al. In-vitro assessment of hypersensitivity syndrome associated with sorbinil. Ann Intern Med 1991; 114: 720–4PubMedGoogle Scholar
  22. 22.
    Knowles S, Shapiro L, Shear N. Serious adverse reactions induced by minocycline: a report of 13 patients and review of the literature. Arch Dermatol 1996; 132(8): 934–9PubMedCrossRefGoogle Scholar
  23. 23.
    Schlienger R, Knowles S, Shear N. Lamotrigine-associated anticonvulsant hypersensitivity syndrome. Neurology 1998; 51: 1172–5PubMedCrossRefGoogle Scholar
  24. 24.
    Dhar G, Pierach CA, Ahamed PN, et al. Diphenylhydantoin-induced hepatic necrosis. Postgrad Med 1974; 56: 128–34PubMedGoogle Scholar
  25. 25.
    Mullick F, Ishak K. Hepatic injury associated with diphenylhydantoin therapy. Am J Clin Pathol 1980; 74: 442–52PubMedGoogle Scholar
  26. 26.
    Cowan L, Bodensteiner JB, Leviton A, et al. Prevalence of the epilepsies in children and adolescents. Epilepsia 1989; 30: 94–106PubMedCrossRefGoogle Scholar
  27. 27.
    Shapiro L, Neumann M, Malkiewicz I, et al. Black race may predict increased severe cutaneous adverse reactions in patients with phenytoin hypersensitivity reactions. Clin Invest Med 1998; 21: 515Google Scholar
  28. 28.
    Hyson C, Sadler M. Cross sensitivity of skin rashes with antiepileptic drugs. Can J Neurol Sci 1997; 24: 245–9PubMedGoogle Scholar
  29. 29.
    Rapp R, Norton J, Young B, et al. Cutaneous reactions in head-injured patients receiving phenytoin for seizure prophylaxis. Neurosurgery 1983; 13: 272–5PubMedCrossRefGoogle Scholar
  30. 30.
    Wilson T, Hojer B, Tomson G, et al. High incidence of a concentration-dependent skin reaction in children treated with phenytoin. BMJ 1978; 1: 1583–6PubMedCrossRefGoogle Scholar
  31. 31.
    Chadwick D, Shaw M, Foy P, et al. Serum anticonvulsant concentrations and the risk of drug-induced skin eruptions. J Neurol Neurosurg Psychiatry 1984; 47: 642–4PubMedCrossRefGoogle Scholar
  32. 32.
    Shapiro L, Shear N. Mechanisms of drug reactions: the metabolic track. Sem Cutan Med Surg 1996; 15: 217–27CrossRefGoogle Scholar
  33. 33.
    Taliercio C, Olney B, Lie J. Myocarditis related to drug hypersensitivity. Mayo Clin Proc 1985; 60: 463–8PubMedGoogle Scholar
  34. 34.
    Stephan W, Parks R, Tempest B. Acute hypersensitivity pneumonitis associated with carbamazepine therapy. Chest 1978; 74: 463–4PubMedCrossRefGoogle Scholar
  35. 35.
    Murphy D, Kronick J, Rieder M. Acute respiratory failure mediated by reactive drug metabolites. Biol Neonat 1995; 67: 223–9CrossRefGoogle Scholar
  36. 36.
    Kleier R, Breneman D, Boiko S. Generalized pustulation as a manifestation of the anticonvulsant hypersensitivity syndrome. Arch Dermatol 1991; 127: 1361–4PubMedCrossRefGoogle Scholar
  37. 37.
    Morkunas A, Miller M. Anticonvulsant hypersensitivity syndrome. Med Toxicol 1997; 13: 727–39Google Scholar
  38. 38.
    Robbie M, Scurry J, Stevenson P. Carbamazepine-induced severe systemic hypersensitivity reaction with eosinophilia. Drug Intell Clin Pharm 1988; 22: 783–4PubMedGoogle Scholar
  39. 39.
    Gupta A, Eggo M, Uetrecht J, et al. Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions to anticonvulsants and sulfonamides. Clin Pharmacol Ther 1992; 51: 56–67PubMedCrossRefGoogle Scholar
  40. 40.
    Callot V, Roujeau J, Bagot M, et al. Drug-induced pseudolymphoma and hypersensitivity syndrome: two different clinical entities. Arch Dermatol 1996; 123: 1315–21CrossRefGoogle Scholar
  41. 41.
    Schreiber M, McGregor J. Pseudolymphoma syndrome. Arch Demi 1968; 97: 297–300CrossRefGoogle Scholar
  42. 42.
    Sinnige H, Boender C, Kuypers E, et al. Carbamazepine-induced pseudolymphoma and immune dysregulation. J Intern Med 1990; 227: 355–8PubMedCrossRefGoogle Scholar
  43. 43.
    Saltzstein S, Ackerman L. Lymphadenopathy induced by anticonvulsant drugs and mimicking clinically and pathologically malignant lymphomas. Cancer 1959; 12: 164–82PubMedCrossRefGoogle Scholar
  44. 44.
    Souteyrand P, d’Incan M. Drug-induced mycosis-fungoides-like lesions. Curr Probl Dermatol 1990; 19: 176–82PubMedGoogle Scholar
  45. 45.
    Wilden J, Scott C. A pseudolymphomatous reaction in soft tissue associated with phenytoin sodium. J Clin Pathol 1978; 31: 76–1764CrossRefGoogle Scholar
  46. 46.
    Rijlaarsdam J, Scheffer E, Meijer CJ, et al. Cutaneous pseudo-T-cell lymphomas: a clinicopathologic study of 20 patients. Cancer 1992; 69: 717–24PubMedCrossRefGoogle Scholar
  47. 47.
    d’Incan M, Souteyrand P, Bignon Y, et al. Hydantoin-induced cutaneous pseudolymphoma with clinical, pathologic, and immunologic aspects of Sezary syndrome. Arch Dermatol 1992; 128: 1371–4PubMedCrossRefGoogle Scholar
  48. 48.
    Yates P, Stockdill G, McIntyre M. Hypersensitivity to carbamazepine presenting as pseudolymphoma. J Clin Pathol 1986; 39: 1224–8PubMedCrossRefGoogle Scholar
  49. 49.
    Shuttleworth D, Graham-Brown R, Williams A, et al. Pseudolymphoma associated with carbmazepine. Clin Exp Dermatol 1984; 9: 421–3PubMedCrossRefGoogle Scholar
  50. 50.
    Sigal-Nahum M, Petit A, Gaulier A, et al. A nodular cutaneous lymphoproliferative disorder during carbamazepine administration. Br J Dermatol 1992; 127: 545–7PubMedCrossRefGoogle Scholar
  51. 51.
    Rijlaarsdam U, Scheffer E, Meijer C, et al. Mycosis fungoides-like lesions associated with phenytoin and carbamazepine therapy. J Am Acad Dermatol 1991; 24: 216–20PubMedCrossRefGoogle Scholar
  52. 52.
    Wolf R, Kahane E, Sandbank M. Mycosis fungoides-like lesions associated with phenytoin therapy. Arch Dermatol 1985;121: 1181–2PubMedCrossRefGoogle Scholar
  53. 53.
    Rosenthal C, Noguera C, Coppola A, et al. Pseudolymphoma with mycosis fungoides manifestations, hyperresponsiveness to diphenylhydantoin, and lymphocyte disregulation. Cancer 1982; 49: 2305–14PubMedCrossRefGoogle Scholar
  54. 54.
    Welykyj S, Gradini R, Nakao J, et al. Carbamazepine-induced eruption histologically mimicking mycosis fungoides. J CutanPathol 1990; 17: 111–6Google Scholar
  55. 55.
    De Vriese A, Philippe J, Van Renterghem D, et al. Carbamazepine hypersensitivity syndrome: report of four cases and review of the literature. Medicine 1995; 74: 144–51PubMedCrossRefGoogle Scholar
  56. 56.
    Savich R, Traisman H. Phenobarbital hypersensitivity reaction. Ill Med J 1986; 169: 232–4Google Scholar
  57. 57.
    Plantin P, Cartier H, Le Bihan G, et al. Syndrome d’hypersensibilite medicamenteuse au cours d’un traitement par acide valproique. Presse Med 1995; 24: 1624PubMedGoogle Scholar
  58. 58.
    Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359–67PubMedCrossRefGoogle Scholar
  59. 59.
    Besag F, Wallace S, Dulac O, et al. Lamotrigine for the treatment of epilepsy in childhood. J Pediatr 1995; 127: 991–7PubMedCrossRefGoogle Scholar
  60. 60.
    Jones D, Chiap V, Resor S, et al. Phenytoin-like hypersensitivity associated with lamotrigine. J Am Acad Dermatol 1997; 36: 1016–8PubMedCrossRefGoogle Scholar
  61. 61.
    Chaffin J, Davis S. Suspected lamotrigine-induced toxic epidermal necrolysis. Ann Pharmacotherapy 1997; 31: 720–3Google Scholar
  62. 62.
    Makin A, Fitt S, Williams R, et al. Fulminant hepatic failure induced by lamotrigine. BMJ 1995; 311: 292PubMedCrossRefGoogle Scholar
  63. 63.
    Nicholson R, Kelly K, Grant I. Leucopenia associated with lamotrigine. BMJ 1995; 310: 504PubMedCrossRefGoogle Scholar
  64. 64.
    Sullivan J, Watson A. Lamotrigine-induced toxic epidermal necrolysis treated with intravenous cyclosporin: a discussion of pathogenesis and immunosuppressive management. Aust J Dermatol 1996; 37: 208–12CrossRefGoogle Scholar
  65. 65.
    Schaub J, Williamson P, Barnes E, et al. Multisystem adverse reaction to lamotrigine [letter]. Lancet 1994; 344: 481PubMedCrossRefGoogle Scholar
  66. 66.
    Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995; 33: 595–7PubMedGoogle Scholar
  67. 67.
    Wadelius M, Karlsson T, Wadelius C, et al. Lamotrigine and toxic epidermal necrolysis [letter]. Lancet 1996; 348: 1041PubMedCrossRefGoogle Scholar
  68. 68.
    Page R, O’Neil M, Yarbrough D, et al. Fatal toxic epidermal necrolysis related to lamotrigine administration. Pharmacotherapy 1998; 18: 392–8PubMedGoogle Scholar
  69. 69.
    Chattergoon D, McGuigan M, Koren G, et al. Multiorgan dysfunction and disseminated intravascular coagulopathy in children receiving lamotrigine and valproic acid. Neurology 1997; 49: 1442–4PubMedCrossRefGoogle Scholar
  70. 70.
    Mitchell P. Paediatric lamotrigine use hit by rash reports. Lancet 1997; 349: 1080CrossRefGoogle Scholar
  71. 71.
    Richens A. Safety of lamotrigine. Epilepsia 1994; 35 Suppl.: S37–40PubMedCrossRefGoogle Scholar
  72. 72.
    Yuen A, Land G, Weatherley B, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511–3PubMedCrossRefGoogle Scholar
  73. 73.
    Spielberg S. In vitro analysis of idiosyncratic drug reactions. Clin Biochem 1986; 19: 142–4PubMedCrossRefGoogle Scholar
  74. 74.
    Houwerzijl J, DeGast G, Nater J. Patch tests in drug eruptions. Contact Dermatitis 1975; 1: 180–92PubMedCrossRefGoogle Scholar
  75. 75.
    Jones M, Fernandez-Herrera J, Dorado J, et al. Epicutaneous test in carbamazepine cutaneous reactions. Dermatology 1994; 188: 18–20PubMedCrossRefGoogle Scholar
  76. 76.
    Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993; 29: 254–7PubMedCrossRefGoogle Scholar
  77. 77.
    Romaguera C, Grimalt F, Vilaplana J, et al. Erythroderma from carbamazepine. Contact Dermatitis 1989; 20: 304–5PubMedCrossRefGoogle Scholar
  78. 78.
    Scerri L, Shall L, Zaki I. Carbamazepine-induced anticonvulsant hypersensitivity syndrome — pathogenic and diagnostic considerations. Clin Exp Dermatol 1993; 18: 540–2PubMedCrossRefGoogle Scholar
  79. 79.
    Puig L, Nadal C, Fernandex-Figueras M, et al. Carbamazepine-induced drug rashes: diagnostic value of patch tests depends on clinico-pathologic presentation. Contact Dermatitis 1996; 34: 435–7PubMedCrossRefGoogle Scholar
  80. 80.
    Houwerzijl J, De Gast G, Nater J, et al. Lymphocyte-stimulation tests and patch tests in carbamazepine hypersensitivity. Clin Exp Immunol 1977; 29: 272–7PubMedGoogle Scholar
  81. 81.
    Silva R, Machado A, Brandao M, et al. Patch test diagnosis in carbamazepine erythroderma. Contact Dermatitis 1986; 15: 254–5PubMedCrossRefGoogle Scholar
  82. 82.
    Spielberg S, Gordon G, Blake D, et al. Anticonvulsant toxicity in vitro: possible role of arene oxides. J Pharmacol Exp Ther 1981; 217: 386–9PubMedGoogle Scholar
  83. 83.
    Riley F, Leeder S. In vitro analysis of metabolic predisposition to drug hypersensitivity reactions. Clin Exp Immunol 1995; 99: 1–6PubMedCrossRefGoogle Scholar
  84. 84.
    Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions. Arch Dermatol 1995; 131: 544–51PubMedCrossRefGoogle Scholar
  85. 85.
    Spielberg S, Gordon G, Blake D, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl JMed 1981; 305: 722–7CrossRefGoogle Scholar
  86. 86.
    Zanni M, von Greyerz S, Schnyder B, et al. T cell reactions in patients showing adverse immune reactions to drugs. Inflamm Res 1996; 45 Suppl.: S79–84PubMedGoogle Scholar
  87. 87.
    Merk H, Baron J, Hertl M, et al. Lymphocyte activation in allergic reactions elicited by small molecular-weight compounds. Int Arch Allergy Immunol 1997; 113: 173–6PubMedCrossRefGoogle Scholar
  88. 88.
    Pirmohamed M, Graham A, Roberts P, et al. Carbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine. Br J Clin Pharmacol 1991; 32: 741–9PubMedCrossRefGoogle Scholar
  89. 89.
    Gleichmann H. Studies on the mechanism of drug sensitization: T-cell dependent popliteal lymph node reaction to diphenylhydantoin. Clin Immunol Immunopathol 1981; 18: 203–11PubMedCrossRefGoogle Scholar
  90. 90.
    Murphy J, Mashman J, Miller J, et al. Suppression of carbamazepine-induced rash with prednisone. Neurology 1991; 41: 144–5PubMedCrossRefGoogle Scholar
  91. 91.
    Vick N. Suppression of carbamazepine-induced skin rash with prednisone. New Engl J Med 1983; 309: 1193–4PubMedGoogle Scholar
  92. 92.
    Smith M, Bleck T. Convulsive disorders: toxicity of anticonvul-sants. Clin Neuropharmacol 1991; 14: 97–115PubMedCrossRefGoogle Scholar
  93. 93.
    Gaedigk A, Spielberg S, Grant D. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 1994; 4: 142–53PubMedCrossRefGoogle Scholar
  94. 94.
    Friedman P, Strickland I, Pirmohamed M, et al. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130: 598–604CrossRefGoogle Scholar
  95. 95.
    Pirmohamed M, Kitteringham N, Breckenridge A, et al. Detection of an autoantibody directed against human liver microsomal protein in a patient with carbamazepine hypersensitivity. Br J Clin Pharmacol 1992; 33: 183–6PubMedCrossRefGoogle Scholar
  96. 96.
    Leeder J, Riley R, Cook V, et al. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther 1992; 263: 360–7PubMedGoogle Scholar
  97. 97.
    Alldredge B, Knutsen A, Ferriero D. Antiepileptic drug hypersensitivity syndrome: in vitro and clinical observations. Pediatr Neurol 1994; 10: 169–71PubMedCrossRefGoogle Scholar
  98. 98.
    Gennis M, Vemuri R, Burns E, et al. Familial occurrence of hypersensitivity to phenytoin. Am J Med 1991; 91: 631–4PubMedCrossRefGoogle Scholar
  99. 99.
    Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433–43PubMedCrossRefGoogle Scholar
  100. 100.
    Knowles S, Shapiro L, Shear N. Serious dermatologic reactions in children. Curr Opin Pediatr 1997; 9: 388–95PubMedCrossRefGoogle Scholar
  101. 101.
    Chopra S, Levell NJ, Cowley G, et al. Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Br J Dermatol 1996; 134: 1109–12PubMedCrossRefGoogle Scholar
  102. 102.
    Sheretz E, Jegasothy B, Lazarus G. Phenytoin hypersensitivity reaction presenting with toxic epidermal necrolysis and severe hepatitis. J Am Acad Dermatol 1985; 12: 178–81CrossRefGoogle Scholar
  103. 103.
    Chaidemenos G, Chrysomallis F, Sombolos K, et al. Plasmapheresis in toxic epidermal necrolysis. Int J Dermatol 1997; 36: 218–21PubMedCrossRefGoogle Scholar
  104. 104.
    Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490–3PubMedCrossRefGoogle Scholar
  105. 105.
    Eames P. Adverse reactions to carbamazepine managed by desensitization. Lancet 1989; I: 509–10CrossRefGoogle Scholar
  106. 106.
    Purves S, Hashimoto S, Tse K. Successful desensitization of patients with carbamazepine allergy [abstract]. Can J Neurol Sci 1988; 15: 237Google Scholar
  107. 107.
    Smith H, Newton R. Adverse reactions to carbamazepine managed by desensitisation [letter]. Lancet 1985; I: 753CrossRefGoogle Scholar
  108. 108.
    Watts D, Bird J. Oxcarbazepine sensitivity treated by desensitisation [letter]. BMJ 1991; 541: 376Google Scholar
  109. 109.
    Zakrzewska J, Ivanyi L. In vitro lymphocyte proliferation by carbmazepine, carbamazepine-10,11 epoxide, and oxcarbazepine in the diagnosis of drug-induced hypersensitivity. J Allergy Clin Immunol 1988; 82: 110–5PubMedCrossRefGoogle Scholar
  110. 110.
    Reents S, Luginbuhl W, Davis S. Phenytoin-carbamazepine cross-sensitivity. Ann Pharmacother 1989; 23: 235–6Google Scholar

Copyright information

© Adis International Limited 1999

Authors and Affiliations

  • Sandra R. Knowles
    • 1
    • 2
  • Lori E. Shapiro
    • 1
    • 2
    • 3
  • Neil H. Shear
    • 1
    • 2
    • 3
    • 4
  1. 1.Division of Clinical Pharmacology, Department of MedicineSunnybrook & Women’s College Health Sciences CentreTorontoCanada
  2. 2.Sunnybrook & Women’s College Health Sciences CentreGlaxo Wellcome — Sunnybrook Drug Safety ClinicTorontoCanada
  3. 3.Division of Dermatology, Department of MedicineSunnybrook & Women’s College Health Sciences CentreTorontoCanada
  4. 4.Drug Safety Research GroupUniversity of TorontoTorontoCanada

Personalised recommendations